Last edition
News about "Eric Hughes"
Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease
Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.
Eric Hughes | 03/09/2026 | By News Bureau
Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study
Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.
Eric Hughes | 18/02/2026 | By News Bureau | 418
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy